Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function

Cell Reports

Volumn 13, Issue 4, 2015, Pages 733-745

  Birket, Matthew J ^a   Ribeiro, Marcelo C ^a   Kosmidis, Georgios ^a   Ward, Dorien ^a   Leitoguinho, Ana Rita ^a   van de Pol, Vera ^a   Dambrot, Cheryl ^a   Devalla, Harsha D ^a   Davis, Richard P ^a   Mastroberardino, Pier G ^b   Atsma, Douwe E ^a   Passier, Robert ^a   Mummery, Christine L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; SOMATOMEDIN C; CARRIER PROTEIN; MYOSIN-BINDING PROTEIN C;

ANIMAL CELL; ARTICLE; BIOENERGY; CELL CONTRACTION; CELL FUNCTION; CELL MEMBRANE; CELL SIZE; CONTROLLED STUDY; EMBRYO; GENE; GENE FUNCTION; GENE MUTATION; HAPLOINSUFFICIENCY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; MALE; MOUSE; MYBPC3 GENE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; ANIMAL; CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; ELECTROPHYSIOLOGY; FLOW CYTOMETRY; GENETICS; METABOLISM; MUTATION;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; ELECTROPHYSIOLOGY; FLOW CYTOMETRY; HUMANS; MICE; MUTATION; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS;

EID: 84945580024     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.025     Document Type: Article

References (66)

1. Alders M., Jongbloed R., Deelen W., van den Wijngaard A., Doevendans P., Ten Cate F., Regitz-Zagrosek V., Vosberg H.P., van Langen I., Wilde A., et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur. Heart J. 2003, 24:1848-1853.
2. Ancey C., Menet E., Corbi P., Fredj S., Garcia M., Rücker-Martin C., Bescond J., Morel F., Wijdenes J., Lecron J.-C., Potreau D. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc. Res. 2003, 59:78-85.
3. Barefield D., Kumar M., Gorham J., Seidman J.G., Seidman C.E., de Tombe P.P., Sadayappan S. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. J. Mol. Cell. Cardiol. 2015, 79:234-243.
4. Bellin M., Casini S., Davis R.P., D'Aniello C., Haas J., Ward-van Oostwaard D., Tertoolen L.G.J., Jung C.B., Elliott D.A., Welling A., et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013, 32:3161-3175.
5. Biondi B., Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004, 24:1-13.
6. Birket M.J., Casini S., Kosmidis G., Elliott D.A., Gerencser A.A., Baartscheer A., Schumacher C., Mastroberardino P.G., Elefanty A.G., Stanley E.G., Mummery C.L. PGC-1α and reactive oxygen species regulate human embryonic stem cell-derived cardiomyocyte function. Stem Cell Reports 2013, 1:560-574.
7. Birket M.J., Ribeiro M.C., Verkerk A.O., Ward D., Leitoguinho A.R., den Hartogh S.C., Orlova V.V., Devalla H.D., Schwach V., Bellin M., et al. Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. Nat. Biotechnol. 2015, 33:970-979. 10.1038/nbt.3271.
8. Bisping E., Ikeda S., Sedej M., Wakula P., McMullen J.R., Tarnavski O., Sedej S., Izumo S., Pu W.T., Pieske B. Transcription factor GATA4 is activated but not required for insulin-like growth factor 1 (IGF1)-induced cardiac hypertrophy. J. Biol. Chem. 2012, 287:9827-9834.
9. Boehmer C., Wilhelm V., Palmada M., Wallisch S., Henke G., Brinkmeier H., Cohen P., Pieske B., Lang F. Serum and glucocorticoid inducible kinases in the regulation of the cardiac sodium channel SCN5A. Cardiovasc. Res. 2003, 57:1079-1084.
10. Chen X., Qian Y., Wu S. The Warburg effect: evolving interpretations of an established concept. Free Radic. Biol. Med. 2015, 79:253-263.
11. Chrysis D., Chagin A., Sävendahl L. Insulin-like growth factor-1 restores dexamethasone-induced heart growth arrest in rats: the role of the ubiquitin pathway. Hormones (Athens) 2011, 10:46-56.
12. Clement C.A., Kristensen S.G., Møllgård K., Pazour G.J., Yoder B.K., Larsen L.A., Christensen S.T. The primary cilium coordinates early cardiogenesis and hedgehog signaling in cardiomyocyte differentiation. J. Cell Sci. 2009, 122:3070-3082.
13. Dambrot C., Braam S.R., Tertoolen L.G.J., Birket M., Atsma D.E., Mummery C.L. Serum supplemented culture medium masks hypertrophic phenotypes in human pluripotent stem cell derived cardiomyocytes. J. Cell. Mol. Med. 2014, 18:1509-1518.
14. Danzi S., Ojamaa K., Klein I. Triiodothyronine-mediated myosin heavy chain gene transcription in the heart. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H2255-H2262.
15. Drawnel F.M., Boccardo S., Prummer M., Delobel F., Graff A., Weber M., Gérard R., Badi L., Kam-Thong T., Bu L., et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014, 9:810-821.
16. El-Armouche A., Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail. Rev. 2009, 14:225-241.
17. Elliott D.A., Braam S.R., Koutsis K., Ng E.S., Jenny R., Lagerqvist E.L., Biben C., Hatzistavrou T., Hirst C.E., Yu Q.C., et al. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 2011, 8:1037-1040.
18. Eschenhagen T., Mummery C., Knollmann B.C. Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes. Cardiovasc. Res. 2015, 105:424-438.
19. Finck B.N., Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 2007, 115:2540-2548.
20. Földes G., Matsa E., Kriston-Vizi J., Leja T., Amisten S., Kolker L., Kodagoda T., Dolatshad N.F., Mioulane M., Vauchez K., et al. Aberrant α-adrenergic hypertrophic response in cardiomyocytes from human induced pluripotent cells. Stem Cell Reports 2014, 3:905-914.
21. Forini F., Nicolini G., Balzan S., Ratto G.M., Murzi B., Vanini V., Iervasi G. Amiodarone inhibits the 3,5,3'-triiodothyronine-dependent increase of sodium/potassium adenosine triphosphatase activity and concentration in human atrial myocardial tissue. Thyroid 2004, 14:493-499.
22. Fraysse B., Weinberger F., Bardswell S.C., Cuello F., Vignier N., Geertz B., Starbatty J., Krämer E., Coirault C., Eschenhagen T., et al. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J. Mol. Cell. Cardiol. 2012, 52:1299-1307.
23. Gerencser A.A., Chinopoulos C., Birket M.J., Jastroch M., Vitelli C., Nicholls D.G., Brand M.D. Quantitative measurement of mitochondrial membrane potential in cultured cells: calcium-induced de- and hyperpolarization of neuronal mitochondria. J. Physiol. 2012, 590:2845-2871.
24. Goncalves R.L.S., Quinlan C.L., Perevoshchikova I.V., Hey-Mogensen M., Brand M.D. Sites of superoxide and hydrogen peroxide production by muscle mitochondria assessed ex vivo under conditions mimicking rest and exercise. J. Biol. Chem. 2015, 290:209-227.
25. Guerra L., Cerbai E., Gessi S., Borea P.A., Mugelli A. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea-pig ventricular myocytes. Br. J. Pharmacol. 1996, 118:1278-1284.
26. Hamanaka R.B., Chandel N.S. Cell biology. Warburg effect and redox balance. Science 2011, 334:1219-1220.
27. Han L., Li Y., Tchao J., Kaplan A.D., Lin B., Li Y., Mich-Basso J., Lis A., Hassan N., London B., et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc. Res. 2014, 104:258-269.
28. Harris S.P., Bartley C.R., Hacker T.A., McDonald K.S., Douglas P.S., Greaser M.L., Powers P.A., Moss R.L. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res. 2002, 90:594-601.
29. Hazeltine L.B., Simmons C.S., Salick M.R., Lian X., Badur M.G., Han W., Delgado S.M., Wakatsuki T., Crone W.C., Pruitt B.L., Palecek S.P. Effects of substrate mechanics on contractility of cardiomyocytes generated from human pluripotent stem cells. Int. J. Cell Biol. 2012, 2012:508294.
30. Iwaki H., Sasaki S., Matsushita A., Ohba K., Matsunaga H., Misawa H., Oki Y., Ishizuka K., Nakamura H., Suda T. Essential role of TEA domain transcription factors in the negative regulation of the MYH 7 gene by thyroid hormone and its receptors. PLoS ONE 2014, 9:e88610.
31. Lan F., Lee A.S., Liang P., Sanchez-Freire V., Nguyen P.K., Wang L., Han L., Yen M., Wang Y., Sun N., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013, 12:101-113.
32. Lang F., Stournaras C., Alesutan I. Regulation of transport across cell membranes by the serum- and glucocorticoid-inducible kinase SGK1. Mol. Membr. Biol. 2014, 31:29-36.
33. Li M., Iismaa S.E., Naqvi N., Nicks A., Husain A., Graham R.M. Thyroid hormone action in postnatal heart development. Stem Cell Res. (Amst.) 2014, 13(3 Pt B):582-591.
34. Liu M., Liu H., Dudley S.C. Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. Circ. Res. 2010, 107:967-974.
35. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., Kolaja K.L., Swanson B.J., January C.T. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2006-H2017.
36. Magyar J., Iost N., Körtvély A., Bányász T., Virág L., Szigligeti P., Varró A., Opincariu M., Szécsi J., Papp J.G., Nánási P.P. Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytes. Pflugers Arch. 2000, 441:144-149.
37. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381:242-255.
38. McConnell B.K., Fatkin D., Semsarian C., Jones K.A., Georgakopoulos D., Maguire C.T., Healey M.J., Mudd J.O., Moskowitz I.P.G., Conner D.A., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ. Res. 2001, 88:383-389.
39. Mookerjee S.A., Goncalves R.L.S., Gerencser A.A., Nicholls D.G., Brand M.D. The contributions of respiration and glycolysis to extracellular acid production. Biochim. Biophys. Acta 2015, 1847:171-181.
40. Moolman J.A., Reith S., Uhl K., Bailey S., Gautel M., Jeschke B., Fischer C., Ochs J., McKenna W.J., Klues H., Vosberg H.P. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000, 101:1396-1402.
41. Ng E.S., Davis R., Stanley E.G., Elefanty A.G. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat. Protoc. 2008, 3:768-776.
42. Pansters N.A., Langen R.C., Wouters E.F., Schols A.M. Synergistic stimulation of myogenesis by glucocorticoid and IGF-I signaling. J. Appl. Physiol. 2013, 114:1329-1339.
43. Pohlmann L., Kröger I., Vignier N., Schlossarek S., Krämer E., Coirault C., Sultan K.R., El-Armouche A., Winegrad S., Eschenhagen T., Carrier L. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ. Res. 2007, 101:928-938.
44. Puente B.N., Kimura W., Muralidhar S.A., Moon J., Amatruda J.F., Phelps K.L., Grinsfelder D., Rothermel B.A., Chen R., Garcia J.A., et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. Cell 2014, 157:565-579.
45. Ribeiro M.C., Tertoolen L.G., Guadix J.A., Bellin M., Kosmidis G., D'Aniello C., Monshouwer-Kloots J., Goumans M.-J., Wang Y.L., Feinberg A.W., et al. Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro--correlation between contraction force and electrophysiology. Biomaterials 2015, 51:138-150.
46. Rog-Zielinska E.A., Thomson A., Kenyon C.J., Brownstein D.G., Moran C.M., Szumska D., Michailidou Z., Richardson J., Owen E., Watt A., et al. Glucocorticoid receptor is required for foetal heart maturation. Hum. Mol. Genet. 2013, 22:3269-3282.
47. Rog-Zielinska E.A., Craig M.-A., Manning J.R., Richardson R.V., Gowans G.J., Dunbar D.R., Gharbi K., Kenyon C.J., Holmes M.C., Hardie D.G., et al. Glucocorticoids promote structural and functional maturation of foetal cardiomyocytes: a role for PGC-1α. Cell Death Differ. 2015, 22:1106-1116.
48. Sakaguchi Y., Cui G., Sen L. Acute effects of thyroid hormone on inward rectifier potassium channel currents in guinea pig ventricular myocytes. Endocrinology 1996, 137:4744-4751.
49. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
50. Sartiani L., Bettiol E., Stillitano F., Mugelli A., Cerbai E., Jaconi M.E. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007, 25:1136-1144.
51. Schakman O., Kalista S., Bertrand L., Lause P., Verniers J., Ketelslegers J.M., Thissen J.P. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 2008, 149:3900-3908.
52. Sherk A.B., Frigo D.E., Schnackenberg C.G., Bray J.D., Laping N.J., Trizna W., Hammond M., Patterson J.R., Thompson S.K., Kazmin D., et al. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 2008, 68:7475-7483.
53. Stöhr A., Friedrich F.W., Flenner F., Geertz B., Eder A., Schaaf S., Hirt M.N., Uebeler J., Schlossarek S., Carrier L., et al. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J. Mol. Cell. Cardiol. 2013, 63:189-198.
54. Synnergren J., Améen C., Jansson A., Sartipy P. Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiol. Genomics 2012, 44:245-258.
55. Troncoso R., Ibarra C., Vicencio J.M., Jaimovich E., Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab. 2014, 25:128-137.
56. van den Berg C.W., Elliott D.A., Braam S.R., Mummery C.L., Davis R.P. Differentiation of human pluripotent stem cells to cardiomyocytes under defined conditions. Methods Mol. Biol. 2015, 10.1007/7651_2014_178.
57. van Dijk S.J., Dooijes D., dos Remedios C., Michels M., Lamers J.M.J., Winegrad S., Schlossarek S., Carrier L., ten Cate F.J., Stienen G.J.M., van der Velden J. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119:1473-1483.
58. van Dijk S.J., Boontje N.M., Heymans M.W., Ten Cate F.J., Michels M., Dos Remedios C., Dooijes D., van Slegtenhorst M.A., van der Velden J., Stienen G.J.M. Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations. Pflugers Arch. 2014, 466:1619-1633.
59. Veerman C.C., Kosmidis G., Mummery C.L., Casini S., Verkerk A.O., Bellin M. Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem?. Stem Cells Dev. 2015, 24:1035-1052.
60. Vidal M., Wieland T., Lohse M.J., Lorenz K. β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway. Cardiovasc. Res. 2012, 96:255-264.
61. Wang G., McCain M.L., Yang L., He A., Pasqualini F.S., Agarwal A., Yuan H., Jiang D., Zhang D., Zangi L., et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 2014, 20:616-623.
62. Witjas-Paalberends E.R., Piroddi N., Stam K., van Dijk S.J., Oliviera V.S., Ferrara C., Scellini B., Hazebroek M., ten Cate F.J., van Slegtenhorst M., et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc. Res. 2013, 99:432-441.
63. Yang X., Rodriguez M., Pabon L., Fischer K.A., Reinecke H., Regnier M., Sniadecki N.J., Ruohola-Baker H., Murry C.E. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J. Mol. Cell. Cardiol. 2014, 72:296-304.
64. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., Thomson J.A., Kamp T.J. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 2009, 104:e30-e41.
65. Zhang Z., Liu R., Townsend P.A., Proud C.G. p90(RSK)s mediate the activation of ribosomal RNA synthesis by the hypertrophic agonist phenylephrine in adult cardiomyocytes. J. Mol. Cell. Cardiol. 2013, 59:139-147.
66. Zhang M., D'Aniello C., Verkerk A.O., Wrobel E., Frank S., Ward-van Oostwaard D., Piccini I., Freund C., Rao J., Seebohm G., et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc. Natl. Acad. Sci. USA 2014, 111:E5383-E5392.